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Dermatitis herpetiformis (DH) is an inﬂammatory cutaneous disease with typical histopathological and immunopathological
ﬁndings clinically characterized by intensely pruritic polymorphic lesions with a chronic-relapsing course. In addition to classic
clinical manifestations of DH, atypical variants are more and more frequently reported and histological and immunological are
added to them, whereas the impact on quality of life of patients with DH is increasingly important to a certain diagnosis. The
aim of this paper is to describe all the possible clinical, histological, and immunological variants of DH in order to facilitate the
diagnosis of a rare disease and, therefore, little known.
1.Introduction
Dermatitis herpetiformis (DH) is an inﬂammatory cuta-
neous disease with typical histopathological and immuno-
pathological ﬁndings clinically characterized by intensely
pruritic polymorphic lesions with a chronic-relapsing
course, ﬁrst described by Duhring in 1884 [1]. In 1966,
M a r k se ta l .[ 2]. reported small-bowel changes in patients
with DH and later gastrointestinal abnormalities described
in patients aﬀected by DH were found to be the same as in
those with celiac disease (CD) [3]. Currently, DH is con-
sidered as the cutaneous manifestation of gluten-dependent
enteropathy, corresponding to CD.
DH is an autoimmune disease, a ﬁnding that is strongly
supported by landmark studies revealing the granular depo-
sition of immunoglobulin A (IgA) in the skin [4–6]. The
same type of immunoglobulin was detected in the small
intestinal mucosa of patient aﬀected by CD, even before
the development of the gluten-induced ﬂat jejunal lesions.
This observation on one hand emphasized the pivotal
pathogenetic role of these immune deposits and from the
other side represented a link between the two diseases [7, 8].
2.ClinicalFeatures
The clinical morphology, in particular a polymorphous pre-
sentation and distribution of the lesions, are the hallmarks
of the DH. Primary lesions of DH consist of grouped erythe-
matous papules, urticarial plaques surmounted by vesicles or
also blisters, which may be often replaced by erosions and
excoriations, because of the intense itching characteristically
associated with this condition. Chronic pruritus and excori-
ations might lead to licheniﬁcation, furthermore a transient
postinﬂammatory hyperpigmentation may occur when the
lesion resolve [9–13]. The symmetrical distribution of the
herpetiform lesions on the extensor surfaces of the elbows
(90%), knees (30%), shoulders, middle line of the back,
buttocks, and sacral region is also a typical feature of the
disease. In particular, Cottini [14]. In 1955 ﬁrst described a
clinical variant with exclusive localization of the lesions on
the knees and elbows symmetrically. Anyway, scalp, nuchal
area, face, and groin may be also involved. No clinical dif-
ferences were described between darker- and white-skinned
individuals, although DH remains primarily a prerogative
of Caucasian population [15]. Most of the patients suﬀer2 Clinical and Developmental Immunology
not only itching but also tickle or burning sensation even
before the onset of the skin lesions.
An uncommon skin manifestation of DH is represented
by purpuric lesions occasionally described on palmo-plantar
surfaces of children, but rarely reported in adults. First
descriptions of DH presenting as purpuric, erythematous,
or hemorrhagic palmar or plantar lesions date from 1971
[16, 17]. Fraser et al. reported such lesions in four of 14
patients with DH [17]. In 1979, Katz and Marks noted that
vesicles may be hemorrhagic, particularly if they are located
on the hands [18]. Moulin et al. [19] eventually described
reported four DH patients with palmar “pseudopurpuric
lesions” which showed typical histologic changes of DH
in three out of four cases. Pierce et al. [20]d e s c r i b e da
27-year-old man with typical DH and additional purpuric
lesions on the palms. In 1986, 47 pediatric series of 47 DH
cases by Karpati et al. [21], 30 (64%) showed red-brown
palmar purpuric lesions, which, however, were not biopsied.
Sometimes, petechial lesions on the ﬁngertips may be the
only symptom of DH, as reported by Moulin et al. [19],
Rutten and Goos [22], Hofmann et al. [23], and recently
Flann et al. [24]. Finally, the last case was described in 2011
byHeinlinetal.[25].Ina15-year-oldfemalewitha6-month
history of recurrent painful petechiae on the ﬁngers and feet,
that was diagnosed as DH after histopathology, direct- and
indirect- immunoﬂuorescence (DIF, IIF).
However,atypicalclinicalpresentationofDHreportedin
the literature includes also palmoplantar keratosis, wheals of
chronic urticaria and lesions mimicking prurigo pigmentosa
[26–28]. In particular, Ohshima et al. [26] in 2003 described
a 63-year-old Japanese man which presented palmoplantar
keratosis, in addition to itchy areas of erythema on the
buttocks and knees with small blisters on the border that
were clinically, histologically, and immunologically compat-
ible with DH. The histologic evaluation of palmoplantar
keratotic lesions showed hyperkeratosis, acanthosis, and
cellular inﬁltration, mainly of lymphocytes, in the dermal
papillae, aspects that were more compatible with psoriasis,
but DIF showed granular IgA deposits in the dermal papillae
conﬁrming the diagnosis of DH. An unusual clinical presen-
tation of DH in children described instead by Powell et al.
[27] in 2004 consisted of chronic urticaria-like skin lesions.
Histologic evaluation showed neutrophilic microabscesses
in the dermal papilla with subepidermal blister formation,
suggestive of DH, that was conﬁrmed by ﬁbrillar IgA
deposition along the basement membrane zone (BMZ) with
papillary accentuation revealed by DIF. Finally, Saito et al.
[28] in 2005 described another atypical clinical presentation
of DH, that was also in a Japanese subject, with features of
prurigo pigmentosa but characterized by both histological
and immunological aspect of DH.
3.Histopathology
The classic histopathologic features of DH seen on light
microscopy include a subepidermal cleft with neutrophils,
that are considered the most likely responsible for the
dermal-epidermal separation [29], and a few eosinophils
at the tips of dermal papillae, that are often accompanied
by a perivascular mixed inﬂammatory inﬁltrate [12, 26].
While these ﬁndings are characteristic, there are a number
of patients who present with pruritic, excoriated skin lesions
with clinical and immunological features of DH in whom
the histologic ﬁndings are nonspeciﬁc and do not conﬁrm
the diagnosis as showed by Warren and Cockerell [30],
which found that 37.5% of DH patients had hematoxylin
and eosin ﬁndings of a lymphocytic inﬁltrate only with
ﬁbrosis in the dermal papillae and ectatic capillaries. The
authors hypothesized that the nonspeciﬁc histologic ﬁndings
could represent both a sampling error on the part of the
clinician taking the biopsy, in particular, choosing excoriated
lesions that correspond to a later stage of the disease, or the
pathology laboratory in sampling the lesion for histology,
considering appropriate a progressive cutting of the tissue
block, or distinct subgroup of dermatitis herpetiformis,
possibly with a separate antigenic target [30].
4.DIF
Actually DIF of uninvolved skin collected in the perilesional
siteisconsideredasthediagnosticgoldstandardforDH[12].
The choice of normal appearing perilesional skin as site of
biopsy specimen for DIF is not random, because in this site
DH patients showed greater IgA deposition than in nonle-
sional or lesional skin as demonstrated by Zone et al. [4].
Two diﬀerent patterns are possible: (a) granular deposits
in the dermal papillae and (b) granular deposits along the
basement membrane. In both cases, deposits are thought to
bepolyclonalbutaremainlycomposedofIgA1[31].Thetwo
patterns may also be present as a combination resulting in
granular IgA deposition along the basement membrane with
accentuation at the tips of the dermal papillae [9–11, 32]. A
third diﬀerent pattern, presents in 50% of Japanese popula-
tions, ﬁrst described in 1993 by Kawana and Segawa [33]a s
“ﬁbrillar pattern,” was subsequently reconsidered by Ko et al.
[34] in 2010. The fundamental diﬀerence between this last
and previous is that the IgA deposition presents as linear
streaks rather than ﬁne granules in the papillary dermis. As
suggested by Ko et al., the ﬁbrillar pattern of IgA deposition
may correlate with a clinical variant of DH or another as
yet undeﬁned disorder, and some case reports of atypical
clinical presentations, that may be urticarial or psoriasiform,
support this hypothesis [35, 36]. The correlation between
the ﬁbrillar DIF pattern and DH is, however, still debated.
Although often the granular and the ﬁbrillar patterns are
associated in patients with DH, the last one alone more often
correlates with atypical features, including atypical clinical
presentations, absence of HLA-B8/DR3DQ2 haplotype, and
lack of gluten-sensitive enteropathy or detectable circulating
autoantibodies [37]. However, not all authors agree that,
considering that the two diﬀerent pattern may be the
expression of a diﬀerent method of sectioning [33].
5.SerologicFindings
Serologic testing is a useful adjunct to tissue-based studies.
Contrary to the other bullous disorders, DH patients have
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basementmembranecomponentsortootheradherentstruc-
tures of the skin, but they have gluten-induced IgA autoanti-
bodies against transglutaminase (TG) 2 and TG3 also called
tissue-TG (t-TG) and epidermal-TG (e-TG), respectively
[13].
TG represents an evolutionary conserved family of Ca+2-
dependentenzymesthatcovalentlycross-linkormodify pro-
teins by formation of an isopeptide bond between a peptide-
bound glutamine residue and a primary amine, most
commonly a lysine residue either within the same or a neigh-
boringpolypeptidechain[38].NinehumantypesofTGwere
identiﬁed and some of them are expressed in the epidermis.
TG2, among them, is the best characterized and also the
most abundant and widely distributed [39]. Over time,
diﬀerent authors demonstrated that the enzymatic activity of
TG2 is implicated in several diseases as Huntington disease,
Alzheimer disease, and CD [40–42]. In particular, CD TG2
catalyzes highly speciﬁc deamidation of gluten peptides
improving the binding of the peptides to the disease-
associated HLA DQ2 and DQ8 molecules and becoming
essential for the T-cell-mediated immune response against
gluten.TG2isalsotheprimaryautoantigenofCDrecognized
by autoantibodies of IgA1 class. These autoantibodies are
considered the main serological marker of CD as disease-
speciﬁc and more generally of gluten-sensitivity diseases and
therefore of DH [12, 38, 43]. Levels of anti-TG2 correlate
with bowel damage and gluten-free diet adherence in
DH/CD patients and are measured using an enzyme-linked
immunosorbent assay (ELISA) [44]. In DH, some authors
have demonstrated an IgA anti-tTG speciﬁcity higher than
90%, and a sensitivity ranging from 47% to 95% [45–49].
However, as demonstrated by S´ ardy et al. [50] the target
autoantigen of DH is represented by TG3, that shares a
64% of homology with TG2 and overlapping sensitivity and
speciﬁcity. As recently demonstrated by Stamnaes et al. [39]
isalsoabletoaccommodateglutenpeptidesassubstratesand
form either thioester or isopeptide-linked complexes with
these peptides stimulating the immune system’s response,
even if it is still unclear how it gets to the skin lesions.
Although promising, the anti-eTG assay has not yet been
approved in the United States for in vitro use to diagnose DH
[51].
In addition to anti-TG2 antibodies, also those anti-EMA
have become relatively sensitive and speciﬁc tools for initial
detectionofgluten-sensitivediseaseand,therefore,ofDH.In
particular, anti-EMA antibodies belong to the IgA1 subclass
and are directed against primate smooth muscle reticular
c o n n e c t i v et i s s u e .T h ed e t e c t i o no fE M Ai sb a s e do na n
indirect immunoﬂuorescence assay on monkey oesophagus
anditismoretime-consumingandoperator-dependentthan
the one of anti-TG2 ELISA testing [52], showing a speciﬁcity
close to 100%, and a sensitivity ranging from 52% to 100%
for the diagnosis of DH [44–47, 53].
Other autoantibodies are shared between DH and CD
such as antigliadin antibodies and antireticulin antibodies,
without, however, the same diagnostic value of anti-TG2 and
anti-EMA.
In 2006, Sugai et al. ﬁrst showed that the most reliable
diagnostic test to identify gluten sensitivity in DH patients
was the detection of antibodies against deamidated synthetic
gliadin-derived peptides, both IgA and IgG isotypes [54].
Recently, a new CD serum marker based on TG2 covalently
cross-linked to deamidated gliadin peptides, coined “neo-
epitope,” was carefully studied by Matthias et al. and data
supporting the use of this new assay (AESKULISA CeliCheck
New Generation) in CD diagnosis were obtained in a
longitudinal study of 2684 eligible subjects demonstrating
a sensitivity of 92,31% and a speciﬁcity of 82,89%, that
were highest when compared to TG2 ELISA test or anti-
EMA tests [55]. The diagnostic value of these antibodies was
also conﬁrmed by Jaskowski et al. [56], which demonstrated
the superior sensitivity of anti-tTG/DGP EIA screen (IgA +
IgG) compared to IgA anti-tTG both in pediatric CD (92,6%
versus 90,7%) and adult DH (65% versus 48,8% and 62%
versus 44% in retrospective and prospective sera, resp.).
Furthermore, very recently, Kasperkiewicz et al. [57] showed
the higher sensitivity of the anti-GAF3X ELISA, a novel CD
serologic assay using deamidated gliadin-analogous fusion
peptides, to detect CD-associated autoantibodies in patients
with DH compared with tests using native gliadin, tTG or
endomysium as substrates.
6. Conclusion
From the data reported above, it seems evident that the
diagnosis of DH can be diﬃcult and, therefore, requires
a complex approach, that should be clinical, histological
and immunological, having regards to the atypical variants
more and more frequently described in the literature. This
becomes crucial since, as it is known, patients with DH
present a signiﬁcant reduction in their quality of life, mainly
due to the need of a lifelong gluten-free diet and, conse-
quently, to a signiﬁcant change in lifestyle and eating habits.
Acknowledgment
This work was supported by the Ministry of Instruction,
University and Research of the Italian Government (PRIN
2008EW3FHK).
References
[1] L. A. Duhring, “Dermatitis herpetiformis,” Journal of the
American Medical Association, vol. 250, no. 2, pp. 212–216,
1983.
[ 2 ]J .M a r k s ,S .S h u s t e r ,a n dA .J .W a t s o n ,“ S m a l l - b o w e lc h a n g e s
in dermatitis herpetiformis,” The Lancet, vol. 2, no. 7476, pp.
1280–1282, 1966.
[3] L. Fry, P. Keir, R. M. McMinn, J. D. Cowan, and A. V.
Hoﬀbrand, “Small-intestinal structure and function and hae-
matological changes in dermatitis herpetiformis,” The Lancet,
vol. 2, no. 7519, pp. 729–733, 1967.
[4] J. J. Zone, L. J. Meyer, and M. J. Petersen, “Deposition of
granular IgA relative to clinical lesions in dermatitis herpeti-
formis,” Archives of Dermatology, vol. 132, no. 8, pp. 912–918,
1996.
[5] L. Fry, “Dermatitis herpetiformis: problems, progress and
prospects,” European Journal ofDermatology, vol.12,no.6,pp.
523–531, 2002.4 Clinical and Developmental Immunology
[6] L. Fry and P. P. Seah, “Dermatitis herpetiformis: an evaluation
of diagnostic criteria,” British Journal of Dermatology, vol. 90,
no. 2, pp. 137–146, 1974.
[7] S. K´ arp´ ati, “Dermatitis herpetiformis: close to unravelling a
disease,” Journal of Dermatological Science, vol. 34, no. 2, pp.
83–90, 2004.
[8] J. J. Zone, “Skin manifestations of celiac disease,” Gastroen-
terology, vol. 128, no. 4, pp. S87–S91, 2005.
[9] L. Fry, “Dermatitis herpetiformis: problems, progress and
prospects,” European Journalof Dermatology, vol.12,no.6,pp.
523–531, 2002.
[10] S. W. Yeh, B. Ahmed, N. Sami, and A. R. Ahmed, “Blistering
disorders: diagnosis and treatment,” Dermatologic Therapy,
vol. 16, no. 3, pp. 214–223, 2003.
[11] M. E. O. Nicolas, P. K. Krause, L. E. Gibson, and J. A.
Murray, “Dermatitis herpetiformis,” International Journal of
Dermatology, vol. 42, no. 8, pp. 588–600, 2003.
[12] M. Caproni, E. Antiga, L. Melani, and P. Fabbri, “Guidelines
for the diagnosis and treatment of dermatitis herpetiformis,”
Journal of the European Academy of Dermatology and Venereol-
ogy, vol. 23, no. 6, pp. 633–638, 2009.
[13] S.K` arp` ati,“Dermatitisherpetiformis,”ClinicsinDermatology,
vol. 30, pp. 56–59, 2012.
[14] G.B.Cottini,“SymmetricaldermatitisherpetiformisofDuhr-
ing localized on the knees and elbows,” Annales de Dermatolo-
g i ee td eS y p h i l i g r a p h i e , vol. 82, pp. 285–286, 1955.
[15] D. Bolotin and V. Petronic-Rosic, “Dermatitis herpetiformis:
part I. Epidemiology, pathogenesis, and clinical presentation,”
Journal of the American Academy of Dermatology, vol. 64, no.
6, pp. 1017–1024, 2011.
[16] R. Marks and E. W. Jones, “Purpura in dermatitis herpeti-
formis,” British Journal of Dermatology, vol. 84, no. 4, pp. 386–
388, 1971.
[17] N. G. Fraser, J. S. Beck, and F. Albert-Recht, “Serum com-
plement (C’3) and immunoglobulin levels in dermatitis her-
petiformis,” British Journal of Dermatology, vol. 85, no. 4, pp.
314–319, 1971.
[18] S. I. Katz and J. M. Marks, “Dermatitis herpetiformis,” in
Dermatology in General Medicine,T .B .F i t z p a t r i c k ,E d . ,p p .
326–330, McGraw-Hill, New York, NY, USA, 2nd edition,
1979.
[19] G. Moulin, D. Barrut, and M. P. Franc, “Pseudopurpuric
palmar localizations of herpetiform dermatitis,” Annales de
Dermatologie et de Venereologie, vol. 110, no. 2, pp. 121–126,
1983.
[20] D. K. Pierce, S. M. Purcell, and R. L. Spielvogel, “Purpuric
papulesandvesiclesofthepalmsindermatitisherpetiformis.,”
Journal of the American Academy of Dermatology, vol. 16, no.
6, pp. 1274–1276, 1987.
[21] S. Karpati, E. Torok, and I. Kosnai, “Discrete palmar and
plantar symptoms in children with dermatitis herpetiformis
Duhring,” Cutis, vol. 37, no. 3, pp. 184–187, 1986.
[22] A. Rutten and M. Goos, “Palmoplantar purpura in dermatitis
herpetiformis Duhring,” Hautarzt, vol. 40, no. 10, pp. 640–
643, 1989.
[23] S. C. Hofmann, D. Nashan, and L. Bruckner-Tuderman, “Pet-
echiae on the ﬁngertips as presenting symptom of dermatitis
herpetiformis Duhring,” Journal of the European Academy of
Dermatology and Venereology, vol. 23, no. 6, pp. 732–733,
2009.
[24] S. Flann, C. Degiovanni, E. K. Derrick, and S. E. Munn, “Two
cases of palmar petechiae as a presentation of dermatitis her-
petiformis,” Clinical and Experimental Dermatology, vol. 35,
no. 2, pp. 206–208, 2010.
[25] J. Heinlin, B. Knoppke, E. Kohl, M. Landthaler, and S. Karrer,
“Dermatitis herpetiformis presenting as digital petechiae,”
Pediatric Dermatology, vol. 29, no. 2, pp. 209–212, 2012.
[26] Y. Ohshima, Y. Tamada, Y. Matsumoto, and T. Hashimoto,
“Dermatitis herpetiformis Duhring with palmoplantar ker-
atosis,” British Journal of Dermatology, vol. 149, no. 6, pp.
1300–1302, 2003.
[27] G. R. Powell, A. L. Bruckner, and W. L. Weston, “Dermatitis
herpetiformis presenting as chronic urticaria,” Pediatric Der-
matology, vol. 21, no. 5, pp. 564–567, 2004.
[28] M. Saito, A. B¨ oer, A. Ishiko, and T. Nishikawa, “Atypical der-
matitis herpetiformis: a Japanese case that presented with
initial lesions mimicking prurigo pigmentosa,” Clinical and
Experimental Dermatology, vol. 31, no. 2, pp. 290–291, 2006.
[29] M. Bowszyc-Dmochowska, A. Seraszek, E. Kaczmarek, J.
Gornowicz, and M. Dmochowski, “Low strength of correla-
tion between the intensity of neutrophil elastase expression
in lesional skin and the level of serum IgA antibodies to
epidermal transglutaminase in dermatitis herpetiformis,” The
Open Autoimmunity Journal. In press.
[30] S. J. P. Warren and C. J. Cockerell, “Characterization of a
subgroup of patients with dermatitis herpetiformis with non-
classical histologic features,” American Journal of Dermatopa-
thology, vol. 24, no. 4, pp. 305–308, 2002.
[31] W. Dieterich, E. Laag, L. Bruckner-Tuderman et al., “Antibod-
ies to tissue transglutaminase as serologic markers in patients
with dermatitis herpetiformis,” J o u rn a lo fI n v e s ti ga ti v eDerm a -
tology, vol. 113, no. 1, pp. 133–136, 1999.
[32] P. Fabbri and M. Caproni, “Dermatitis herpetiformis,”
Orphanet Encyclopedia, 2005, http://www.orpha.net/data/
patho/GB/uk-DermatitisHerpetiformis.pdf.
[33] S. Kawana and A. Segawa, “Confocal laser scanning micro-
scopic and immunoelectron microscopic studies of the ana-
tomical distribution of ﬁbrillar IgA deposits in dermatitis
herpetiformis,” Archives of Dermatology, vol. 129, no. 4, pp.
456–459, 1993.
[ 3 4 ]C .J .K o ,O .R .C o l e g i o ,J .E .M o s s ,a n dJ .M .M c N i ﬀ,
“Fibrillar IgA deposition in dermatitis herpetiformis—an
underreported pattern with potential clinical signiﬁcance,”
Journal of Cutaneous Pathology, vol. 37, no. 4, pp. 475–477,
2010.
[ 3 5 ]S .E .C l e m e n t s ,C .M .S t e f a n a t o ,B .B h o g a l ,a n dR .W .
Groves, “Atypical dermatitis herpetiformis with ﬁbrillar IgA
deposition: CPC-8,” British Journal of Dermatology, vol. 157,
article 17, 2007.
[36] S. A. V. Jones, B. S. Bhogal, and M. M. Black, “Fibrillar
IgA deposition may be associated with atypical dermatitis
herpetiformis—a report of two cases,” Journal of the European
Academy of Dermatology and Venereology,v o l .7 ,n o .3 ,p p .
270–278, 1996.
[37] M. Shibahara, H. Nanko, M. Shimizu et al., “Dermatitis her-
petiformis in Japan: an update,” Dermatology, vol. 204, no. 1,
pp. 37–42, 2002.
[38] D. Aeschlimann and V. Thomazy, “Protein crosslinking in
assembly and remodelling of extracellular matrices: the role
of transglutaminases,” C o n n e c t i v eT i s s u eR e s e a r c h , vol. 41, no.
1, pp. 1–27, 2000.
[39] J. Stamnaes, S. Dorum, B. Fleckenstein, D. Aeschlimann, and
L. M. Sollid, “Gluten T cell epitope targeting by TG3 and TG6;
implications for dermatitis herpetiformis and gluten ataxia,”
Amino Acids, vol. 39, no. 5, pp. 1183–1191, 2010.
[40] Ø. Molberg, S. N. Mcadam, R. K¨ orner et al., “Tissue trans-
glutaminase selectively modiﬁes gliadin peptides that areClinical and Developmental Immunology 5
recognized by gut-derived T cells in celiac disease,” Nature
Medicine, vol. 4, no. 6, pp. 713–717, 1998.
[41] Z. Nemes, L. F´ es¨ us, A. ´ Egerh´ azi, A. Keszthelyi, and I. M.
Degrell, “Nε(γ-glutamyl)lysine in cerebrospinal ﬂuid marks
Alzheimertypeandvasculardementia,”NeurobiologyofAging,
vol. 22, no. 3, pp. 403–406, 2001.
[42] T. M. Jeitner, M. B. Bogdanov, W. R. Matson et al., “Nε-(γ-L-
glutamyl)-L-lysine (GGEL) is increased in cerebrospinal ﬂuid
of patients with Huntington’s disease,” Journal of Neurochem-
istry, vol. 79, no. 5, pp. 1109–1112, 2001.
[43] A. Fasano and C. Catassi, “Current approaches to diagnosis
and treatment of celiac disease: an evolving spectrum,” Gas-
troenterology, vol. 120, no. 3, pp. 636–651, 2001.
[ 4 4 ]A .R o s t o m ,J .A .M u r r a y ,a n dM .F .K a g n o ﬀ,“ A m e r i c a ng a s -
troenterological association (AGA) institute technical review
on the diagnosis and management of celiac disease,” Gastroen-
terology, vol. 131, no. 6, pp. 1981–2002, 2006.
[45] A. M. Desai, R. S. Krishnan, and S. Hsu, “Medical Pearl: using
tissue transglutaminase antibodies to diagnose dermatitis her-
petiformis,” Journal of the American Academy of Dermatology,
vol. 53, no. 5, pp. 867–868, 2005.
[ 4 6 ]W .M .P o r t e r ,D .J .U n s w o r t h ,R .J .L o c k ,C .M .H a r d m a n ,B .
S. Baker, and L. Fry, “Tissue transglutaminase antibodies in
dermatitisherpetiformis,”Gastroenterology,vol.117,no.3,pp.
749–750, 1999.
[47] I. Koop, R. Ilchmann, L. Izzi et al., “Detection of autoanti-
bodies against tissue transglutaminase in patients with celiac
disease and dermatitis herpetiformis,” American Journal of
Gastroenterology, vol. 95, no. 8, pp. 2009–2014, 2000.
[48] M. Caproni, C. Cardinali, D. Renzi, A. Calabr´ o, and P. Fabbri,
“Tissue transglutaminase antibody assessment in dermatitis
herpetiformis,” British Journal of Dermatology, vol. 144, no. 1,
pp. 196–197, 2001.
[49] V. Kumar, M. Jarzabek-Chorzelska, J. Sulej, M. Rajadhyaksha,
and S. Jablonska, “Tissue transglutaminase and endomysial
antibodies—diagnostic markers of gluten-sensitive enteropa-
thy in dermatitis herpetiformis,” Clinical Immunology, vol. 98,
no. 3, pp. 378–382, 2001.
[50] M. S´ a r d y ,S .K ´ arp´ ati, B. Merkl, M. Paulsson, and N. Smyth,
“Epidermal transglutaminase (TGase 3) is the autoantigen of
dermatitis herpetiformis,” Journal of Experimental Medicine,
vol. 195, no. 6, pp. 747–757, 2002.
[51] T. D. Jaskowski, T. Hamblin, A. R. Wilson et al., “IgA anti-
epidermal transglutaminase antibodies in dermatitis herpeti-
formis and pediatric celiac disease,” Journal of Investigative
Dermatology, vol. 129, no. 11, pp. 2728–2730, 2009.
[52] M. F. Kagnoﬀ, “AGA institute medical position statement on
the diagnosis and management of celiac disease,” Gastroen-
terology, vol. 131, no. 6, pp. 1977–1980, 2006.
[53] J. Alonso-llamazares, L. E. Gibson, and R. S. Rogers, “Clinical,
pathologic, and immunopathologic features of dermatitis
herpetiformis: review of the Mayo Clinic experience,” Inter-
national Journal of Dermatology, vol. 46, no. 9, pp. 910–919,
2007.
[54] E.Sugai,E.Smecuol,S.Nivelonietal.,“Celiacdiseaseserology
in dermatitis herpetiformis. Which is the best option for
detecting gluten sensitivity?” Acta Gastroenterologica Lati-
noamericana, vol. 36, no. 4, pp. 197–201, 2006.
[55] T. Matthias, S. Pfeiﬀer, C. Selmi, and M. E. Gershwin, “Diag-
nostic challenges in celiac disease and the role of the tissue
transglutaminase-neo-epitope,” Clinical Reviews in Allergy
and Immunology, vol. 38, no. 2-3, pp. 298–301, 2010.
[56] T. D. Jaskowski, M. R. Donaldson, C. M. Hull et al., “Novel
screening assay performance in pediatric celiac disease and
adult dermatitis herpetiformis,” Journal of Pediatric Gastroen-
terology and Nutrition, vol. 51, no. 1, pp. 19–23, 2010.
[57] M. Kasparkiewicz, C. D¨ ahnrich, C. Probst et al., “Novel assay
for detecting celiac disease-associated autoantibodies in der-
matitis herpetiformis using deamidated gliadin-analogous
fusion peptides,” Journal of the American Academy of Derma-
tology, vol. 66, pp. 583–588, 2012.